Observations from a Hospital Executive (Decision Maker) on the Article “Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly: A Retrospective Claims Data Analysis”  by Wong, Peter K.
Volume 6 • Number 5 • 2003
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/03/$15.00/532 532–533 532
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152003 ISPORSeptember/October 200365532533CommentaryObservations from a Hospital ExecutiveWong
Observations from a Hospital Executive (Decision Maker) 
on the Article “Long-Term Resource Use and Cost of 
Percutaneous Transluminal Coronary Angioplasty versus 
Stenting in the Elderly: A Retrospective Claims Data Analysis”
Peter K. Wong, PhD, MBA, RPh
Good Samaratin Hospital
Who should pay for new innovations?
Coronary stenting has demonstrated superiority
to the angioplasty percutaneous transluminal coro-
nary angioplasty (PTCA) in both the restenosis
(18% vs. 32%) and revascularization for target ves-
sel in 6 months following the initial procedure
(10% vs. 27%) [1]. While the initial hospital cost
for stenting is higher than the PTCA (owing to the
price of the stent), the 1-year follow-up hospital
costs for the PTCA eventually catch up with the ini-
tial higher cost as shown in a randomized clinical
trial by Cohen et al. [2]. There was no accounting
for the outpatient and physician costs in this clinical
trial. The article by Subramanian et al. [3] in this
issue of Value in Health provides us a method of
evaluating the initial hospital and 2-year follow-up
costs of PTCA vs. stenting using the Medicare
claims data. In their analysis, they included the out-
patient, physician, skilled nursing facilities, and
home health costs. It is a more comprehensive anal-
ysis and provides the decision makers a better
understanding of the long-term costs associated
with these two treatments. The results of the study
indicate that there is no signiﬁcant difference in the
initial hospitalization and 2-year follow-up costs
comparing the bare metal stenting with the PTCA.
From the payer perspective, introduction of the
stenting technology has created no long-term addi-
tional cost to Medicare. In fact, the Medicare pro-
gram had achieved cost avoidance (1995–1998) for
several years by delaying the reimbursement while
concurrently gaining the downstream cost savings
from decreased revascularizations. In spite of reim-
bursement, the additional dollars did not cover the
expenses incurred by hospitals in 1998. The addi-
tional reimbursement in 1998 reported by Subra-
manian et al. was $1259 [3]. The cost of each stent
at that time was from $1200 to $1500 depending
on the type of stent and the hospital’s buying con-
tract. The average number of stents implanted per
patient was 1.7 [4]. Using the lower price for cal-
culation, the additional cost per case to the hospital
was $2040. The difference between the additional
cost and extra reimbursement was still $781 lost to
the hospital.
The implementation of the stenting treatment
gained no long-term cost savings. The 2-year cost
analysis yielded a cost-neutral position. We can
argue that there was no cost-saving beneﬁt gained
by the payer. The rate of return for the investment in
paying for the stents is zero. All the cost savings
procured from the stent treatment had passed to the
producers.
From the patient’s perspective, the improved clin-
ical outcome with the new innovative stenting tech-
nology has resulted in fewer revascularizations. It
deﬁnitely is an improvement to their quality of life.
From a hospital provider “cost” perspective, it is a
losing situation. Although the stenting group had
shorter average length of stay for hospital admis-
sions in the second year of the follow-up period, the
cost savings from the last several days of these pro-
cedure admissions could not cover the expenditure
for the stents. Most of the costs for the procedure
admissions are accounted for during the early days
of the total length of stay. Therefore, hospitals were
ﬁnancing the downstream health beneﬁt gained
from stenting technology between 1995 and 1998.
Even though there was reimbursement, it was insuf-
ﬁcient. As a decision maker for a hospital, my col-
leagues and I struggle daily to prioritize the resource
allocation in hope of the best care for our patients
with the limited available dollars. The article by
Subramanian et al. is very informative. It is com-
forting to know that we are providing a better care
to our patients and with no signiﬁcant long-term
additional cost to our payers. From a societal per-
spective, the stenting treatment is certainly effective,
but at whose expenses? The results of this study
show that all savings from the decrease in revascu-
larizations and rehospitalizations had gone to the
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price of stents. From health-care policy perspective,
should the producer assume all the cost savings, or
beneﬁts, by setting the product price at the maxi-
mum dollars saved or should some of these beneﬁts
be shared with other parties involved in the process
in the society?—Peter K. Wong, PhD, MBA, RPh,
Good Samaritan Hospital, Center for Outcomes
Research & Clinical Effectiveness, Dayton, OH
45406, USA.
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